Therapeutic strategies based on glucagon-like peptide 1.
about
Gastrointestinal hormones regulating appetitePrevalence, predisposition and prevention of type II diabetes.Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsPharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjectsDifferential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort studyVildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris.Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS).Significance of Microbiota in Obesity and Metabolic Diseases and the Modulatory Potential by Medicinal Plant and Food IngredientsBioreducible polymers for therapeutic gene deliveryEfficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide.Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism.Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.Lixisenatide: evidence for its potential use in the treatment of type 2 diabetesMetabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetesPolymer-based delivery of glucagon-like Peptide-1 for the treatment of diabetes.Uncoupling protein 2 regulates glucagon-like peptide-1 secretion in L-cells.Association of TCF7L2 gene polymorphisms with reduced acute insulin response in Hispanic Americans.Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding.An inhibitory antibody against dipeptidyl peptidase IV improves glucose tolerance in vivoDipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.B-cell translocation gene 2 positively regulates GLP-1-stimulated insulin secretion via induction of PDX-1 in pancreatic β-cells.Stopped-Flow Studies of the Reduction of the Copper Centers Suggest a Bifurcated Electron Transfer Pathway in Peptidylglycine Monooxygenase.Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes.Vildagliptin: a new oral treatment for type 2 diabetes mellitusLinagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry.Liraglutide: clinical pharmacology and considerations for therapy.Clinical pharmacokinetics and pharmacodynamics of vildagliptin.Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: a European expert recommendation.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.
P2860
Q24669951-C5C12B9C-EA54-4A20-B89C-9E4C7AFBC94AQ24815863-D3921F80-78D6-4362-980A-744F3558FF61Q26749524-23842715-3B4C-4AAA-830B-6A7A1F640889Q28252893-4B468B56-A45E-4DB0-A08C-04179989CB89Q28547367-CABC7092-D643-40A6-9E41-DF3DFE7816E9Q33237060-50ED4445-4E07-49C2-AED6-B1C9A61C5E60Q33415965-821CEE4D-710C-4C3D-86F0-9B5A50015538Q33525709-CD0D3B9E-1FCC-4EA1-B258-F59AB60E7CE4Q33858968-C4D1DA4C-3F3E-4F5A-8352-306AF607C0F9Q34079568-7F76FAC4-FEE2-4B74-9FC9-D4CA0C133B1AQ34407865-42FBC637-4844-4E77-AF5A-B337A52B7C1BQ34653078-792C4984-E361-4836-A8FA-5067AD443F17Q34659509-0BFA6701-8E41-4386-8FBA-968FE12C66D2Q35087846-CC0E5999-6A26-40EF-873A-CDE012B476CDQ35285238-38DC3C40-5B44-4353-A44F-7D4368401E04Q35372804-59E16756-DB45-406C-B3FD-171C42824F0DQ36012896-3D84941D-7CF0-40BC-9556-0E986117BDE5Q36014423-46EDD6F6-57CE-430A-9CE3-47E9DC4618F9Q36093376-87B520F9-C98E-41F0-B5F3-CF1C07FB237CQ36360784-F0D4B1EF-7F27-40BB-880B-73993377AB1CQ36407215-7D8CF81D-CB9B-4252-BB1E-4A9362BE1B0AQ36510864-43400DA8-4F2D-48D2-B465-B0E6F5E1CCB6Q36526318-A897BF98-12E9-4465-8E02-9FA84F0E2391Q36764031-98C451DF-98DB-4E7E-9E98-CA2E583CBBBDQ36907211-1EA750E7-6617-43EF-821F-BCE2EE509A99Q36934070-E78E66CF-0EFA-4273-BFB0-8FC70FA14D0FQ37106470-89E4D3DA-4F5C-42E0-9809-D0FBB9549B4BQ37280699-E8CBDA24-6A39-4B06-A349-0572587C408FQ37345249-40A8C0C1-F591-4F4C-AF4E-A71EB9687199Q37428878-9747AC17-44CA-40C9-9219-58238DEBBA8FQ37641377-65A097E7-B12B-43CC-8B8D-DBED3673694EQ37772523-8F164577-83B7-4F48-A486-389397A8C251Q37866299-75699F8D-EB6B-48CC-A7CD-6FD49049A08CQ37893563-EC189799-AE32-4BD1-9CEC-AB5D31DC07B5Q37933408-5DCCBD71-2C2B-4CDB-A5BD-1BD3C4EE459DQ37984567-31887B09-C7EA-43A1-9E90-BA2E94284B7DQ37995760-7D848096-1BD4-4FB8-B7EC-BF4B2975C90AQ38024321-491C02C4-C421-4FE1-BE35-84CD6283025EQ38024383-754B9BC0-1BC7-4A2D-AFBF-00C2112C030EQ38110433-7AF064A0-7331-49E0-812F-0ED2A191CF66
P2860
Therapeutic strategies based on glucagon-like peptide 1.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Therapeutic strategies based on glucagon-like peptide 1.
@ast
Therapeutic strategies based on glucagon-like peptide 1.
@en
type
label
Therapeutic strategies based on glucagon-like peptide 1.
@ast
Therapeutic strategies based on glucagon-like peptide 1.
@en
prefLabel
Therapeutic strategies based on glucagon-like peptide 1.
@ast
Therapeutic strategies based on glucagon-like peptide 1.
@en
P1433
P1476
Therapeutic strategies based on glucagon-like peptide 1
@en
P2093
Carolyn F Deacon
P304
P356
10.2337/DIABETES.53.9.2181
P407
P577
2004-09-01T00:00:00Z